���߲ݴ�ý

All publications

Journal articles

• Al-janabi H, Moyes K, Allen R, Fisher M, Crespo M, Gurel B, Rescigno P, de Bono J, Nunns H, Bailey C , Junker-Jensen A et al (2024) . Journal for ImmunoTherapy of Cancer, 12(7), e009368-e009368.
• Huang Q, Brown J & Mitchell C (2024) . British Journal of General Practice, 74(suppl 1), bjgp24X737637-bjgp24X737637.
• Handforth C, Paggiosi MA, Jacques R, Gossiel F, Eastell R, Walsh JS & Brown JE (2024) . Journal of Bone Oncology, 47.
• Brown J, Santini D, Charnley N, Ogareva A, Chisholm A & Jones R (2024) . Cancer Treatment Reviews, 102792-102792.
• Jones C, Sachdeva A, Murphy L, Murray M, Brown L, McCloskey E, Atard G, Parmar M, James N, Sydes M , Clarke N et al (2024) . Journal of Bone Oncology, 45, 100568-100568.
• Wood SL, Lopez-Guajardo A, Oliva M, Collins M, Clézardin P, Croset M & Brown JE (2024) . Journal of Bone Oncology, 45, 100570-100570.
• Wood SL, Lopez-Guajardo A, Oliva MR, Collins M, Pham K, Dunning M, Chambers EV & Brown JE (2024) . Journal of Bone Oncology, 45, 100566-100566.
• Brown J, Paggiosi M, Rathbone E, Dodwell D, Cameron D, Gregory W, Eastell R & Coleman R (2024) . Journal of Bone Oncology, 45, 100529-100529.
• Jones C, Gray S, Brown M, Brown J, McCloskey E, Rai BP, Clarke N & Sachdeva A (2024) . European Urology Oncology.
• Vasudev NS, Ainsworth G, Brown S, Pickering L, Waddell T, Fife K, Griffiths R, Sharma A, Katona E, Howard H , Velikova G et al (2023) . J Clin Oncol, JCO2300236.
• Jones C, Dutey-Magni P, Murphy LR, Murray M, Brown JE, McCloskey E, Parmar MK, James ND, Sydes MR, Brown LC , Clarke NW et al (2023) . Annals of Oncology, 34, S956-S957.
• Huang Q, Grossett V, Daley S, Fryer K, Brown J & Mitchell C (2023) . British Journal of General Practice, 73(suppl 1), bjgp23X733797-bjgp23X733797.
• Mitchell C, Fryer K, Guess N, Aminu H, Jackson B, Gordon A, Reynolds J, Huang Q, Jayasooriya S, Mawson R , Lawy T et al (2023) . British Journal of General Practice, 73(732), 326-329.
• Brown JE, Royle K-L, Gregory W, Ralph C, Maraveyas A, Din O, Eisen T, Nathan P, Powles T, Griffiths R , Jones R et al (2023) . The Lancet Oncology, 24(3), 213-227.
• Challapalli A, Ratnayake G, McGrane J, Frazer R, Gupta S, Parslow DS, Kingdon SJ, Lydon A, Sharma A, Tuthill M , McCusker C et al (2022) . Annals of Oncology, 33, S1215-S1215.
• Winter M, Coleman R, Kendall J, Palmieri C, Twelves C, Howell S, MacPherson I, Wilson C, Purohit K, Gath J , Taylor C et al (2022) . Journal of Bone Oncology, 35, 100442-100442.
• Brown JE & Symeonides SN (2022) . Eur Urol.
• Wood S, Lopez-Guajardo A, Oliva M & Brown J (2022) . Bone Reports, 16, 101362-101362.
• Wood S, Lopez A, Oliva M & Brown J (2022) . Bone Reports, 16, 101363-101363.
• Lovero D, D’Oronzo S, Palmirotta R, Cafforio P, Brown J, Wood S, Porta C, Lauricella E, Coleman R & Silvestris F (2022) . British Journal of Cancer, 126(3), 419-429.
• Porter I, Theodoulou E, Holen I, Harper-Wynne C, Baron-Hay S, Wilson C & Brown J (2021) . Journal of Bone Oncology, 31, 100402-100402.
• Andrews RE, Brown JE, Lawson MA & Chantry AD (2021) . Journal of Clinical Medicine, 10(17).
• Brown JE, Royle K-L, Ralph C, Meads D, Martin A, Howard H, Linsley C, Swain J, Powles TB, Jones R , Eisen T et al (2021) . Annals of Oncology, 32, S1303-S1304.
• Brown JE, Harrow B, Marciniak A, McCarthy C, Cirneanu L & Protheroe A (2021) . Annals of Oncology, 32, S701-S701.
• Vasudev NS, Ainsworth G, Brown S, Pickering L, Waddell TS, Fife K, Griffiths R, Sharma A, Katona E, Howard H , Velikova G et al (2021) . Annals of Oncology, 32, S1304-S1305.
• Brown JE, Wood SL, Confavreux C, Abe M, Weilbaecher K, Hadji P, Johnson RW, Rhoades JA, Edwards CM, Croucher PI , Juarez P et al (2021) . Journal of Bone Oncology, 29.
• Reale S, Turner RR, Sutton E, Steed L, Taylor SJC, Morrissey D, Doherty P, Greenfield DM, Collinson M, Hewison J , Brown J et al (2021) . Scientific Reports, 11(1).
• D'Oronzo S, Wood S & Brown JE (2021) . Bone, 147, 115907-115907.
• D'Oronzo S, Gregory W, Nicholson S, Chong YK, Brown J & Coleman R (2021) . Journal of Bone Oncology, 28.
• D'oronzo S, Lovero D, Palmirotta R, Cafforio P, Brown J, Wood S, Porta C & Silvestris F (2021) . Bone Reports, 14, 100840-100840.
• Turner RR, Arden MA, Reale S, Sutton E, Taylor SJC, Bourke L, Greenfield DM, Morrissey D, Brown J, Doherty P , Rosario DJ et al (2021) . BMC Health Services Research, 21.
• Reale S, Turner RR, Sutton E, Taylor SJC, Bourke L, Morrissey D, Brown J, Rosario DJ & Steed L (2021) . BMC Health Services Research, 21(1).
• Winter M, Kendall J, Brown S, Rathbone E, Wilson C, Howell S, Twelves C, Palmieri C, Anand A, MacPherson I , Coleman R et al (2021) . Cancer Research, 81(4_Supplement).
• Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2021) . Molecular Cancer Therapeutics, 20(3), 589-601.
• Handforth C, Burkinshaw R, Freeman J, Brown JE, Snowden JA, Fearnside J, Coleman RE & Greenfield DM (2021) . Supportive Care in Cancer, 29(2), 1145-1145.
• Levy DT, Sánchez‐Romero LM, Li Y, Yuan Z, Travis N, Jarvis MJ, Brown J & McNeill A (2021) . Addiction, 116(5), 1196-1211.
• Coleman R, Brown J, Rathbone E, Flanagan L, Reid A, Kendall J, Howell S, Twelves C, Palmieri C, Anand A , MacPherson I et al (2020) . Trials, 21(1).
• Eisen T, Frangou E, Oza B, Ritchie AWS, Smith B, Kaplan R, Davis ID, Stockler MR, Albiges L, Escudier B , Larkin J et al (2020) . Journal of Clinical Oncology, 38(34), 4064-4075.
• Brown JE, Handforth C, Compston JE, Cross W, Parr N, Selby P, Wood S, Drudge-Coates L, Walsh JS, Mitchell C , Collinson FJ et al (2020) . Journal of Bone Oncology, 25.
• Rossi SH, Blick C, Handforth C, Brown JE & Stewart GD (2020) . European Urology Focus, 6(5), 991-998.
• Hall PE, Shepherd STC, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E, Bahl A , Fife K et al (2020) . European Urology Focus, 6(5), 999-1005.
• D'Oronzo S, Lovero D, Palmirotta R, Cafforio P, Brown J, Wood S, Cives M, Tucci MG, Stucci LS, Coleman RE & Silvestris F (2020) . Annals of Oncology, 31, S26-S26.
• Baron-Hay S, Theodoulou E, Porter I, Wilson C, Holen I, Harper-Wynne C & Brown J (2020) Abstract P2-18-08: Inclusion of adjuvant bone-modifying agents for early breast cancer into standard clinical practice: Challenges and lessons learnt from an international collaboration. Abstracts: 2019 San Antonio Breast Cancer Symposium.
• Atala A (2019) . Journal of Urology, 202(6), 1101-1101.
• A M El Badri S, Salawu A & Brown JE (2019) . Current Osteoporosis Reports, 17(6), 527-537.
• Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G, Brunt A, Kuemmel S , Ruiz I et al (2019) . JAMA Oncology, 5(11), 1556-1564.
• Brown JE, Westbrook JA & Wood SL (2019) . Cancer Informatics, 18, 1-3.
• Harnan S, Tappenden P, Cooper K, Stevens J, Bessey A, Rafia R, Ward S, Wong R, Stein RC & Brown J (2019) . Health Technology Assessment, 23(30), 1-328.
• Rossi SH, Fielding A, Blick C, Handforth C, Brown JE & Stewart GD (2019) . European Urology, 75(6), 891-893.
• Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter-Howard F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury S et al (2019) . Clinical Cancer Research, 25(9), 2769-2782.
• D'Oronzo S, Coleman R, Brown J & Silvestris F (2019) . Journal of Bone Oncology, 15.
• Probert C, Dottorini T, Speakman A, Hunt S, Nafee T, Fazeli A, Wood S, Brown JE & James V (2019) . Oncogene, 38(-), 1751-1763.
• Westbrook JA, Wood SL, Cairns DA, McMahon K, Gahlaut R, Thygesen H, Shires M, Roberts S, Marshall H, Oliva M , Dunning MJ et al (2019) . The Journal of Pathology, 247(3), 381-391.
• Handforth C, Burkinshaw R, Freeman J, Brown JE, Snowden JA, Coleman RE & Greenfield DM (2019) . Supportive Care in Cancer, 27(5), 1755-1763.
• Brown JE & Wood SL (2018) . Annals of Translational Medicine, 6(S1), S71-S71.
• Coleman RE, Collinson M, Gregory W, Marshall H, Bell R, Dodwell D, Keane M, Gil M, Barrett-Lee P, Ritchie D , Bowman A et al (2018) . Journal of Bone Oncology, 13, 123-135.
• Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Hutchinson JN, Haider M-T, Rhee CS, Qin Y, Gregory WM , Garrido-Castro AC et al (2018) . Cancer Research, 78(18), 5300-5314.
• Brown J, Rathbone E, Hinsley S, Gregory W, Gossiel F, Marshall H, Burkinshaw R, Shulver H, Thandar H, Bertelli G , Maccon K et al (2018) . JNCI: Journal of the National Cancer Institute, 110(8), 871-879.
• Greasley RU, Turner R, Collins K, Brown J, Bourke L & Rosario DJ (2018) . BMC Cancer, 18(1).
• Wilson C, Bell R, Hinsley S, Marshall H, Brown J, Cameron D, Dodwell D & Coleman R (2018) . European Journal of Cancer, 94, 70-78.
• Handforth C, D’Oronzo S, Coleman R & Brown J (2018) . Calcified Tissue International, 102(2), 251-264.
• D’Oronzo S, Brown J & Coleman R (2017) . Journal of Bone Oncology, 9, 1-9.
• Zekri J, Marples M, Taylor D, Kandukurti K, McParland L & Brown JE (2017) . Journal of Bone Oncology, 8, 13-17.
• Kelly-Morland C, Zhong J, Goh V, Wah T, Ralph C, Thistlethwaite F, Patel P, Nathan P, Eisen T, Gregory W , McParland L et al (2017) . Annals of Oncology, 28, v315-v315.
• D'Oronzo S, Brown J & Coleman R (2017) . European Journal of Cancer Care.
• Lipton A, Smith MR, Fizazi K, Stopeck AT, Henry D, Brown J, Shore ND, Saad F, Spencer A, Zhu L & Warner DJ (2016) . Clinical Cancer Research.
• GBD 2015 Mortality and Causes of Death Collaborators (2016) . The Lancet, 388(10053), 1459-1544.
• James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I, Collins S, McLaren D, O'Sullivan J, Parker C , Porfiri E et al (2016) . Health Technol Assess, 20(53), 1-288.
• GlobalSurg Collaborative (2016) . British Journal of Surgery, 103(8), 971-988.
• Andronis L, Goranitis I, Pirrie S, Pope A, Barton D, Collins S, Daunton A, McLaren D, O'Sullivan JM, Parker C , Porfiri E et al (2016) . BJU International.
• Orsini L, Gilbert D, Podicheti R, Jansen M, Brown JB, Solari OS, Spanier KI, Colbourne JK, Rush D, Decaestecker E , Asselman J et al (2016) . Scientific Data, 3.
• Powles T, Lackner MR, Oudard S, Escudier B, Ralph C, Brown JE, Hawkins RE, Castellano D, Rini BI, Staehler MD , Ravaud A et al (2016) . Journal of Clinical Oncology, 34(14), 1660-1668.
• Powles T, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E, Bhal A, Fife K , Webb A et al (2016) . Annals of Oncology, 27(5), 880-886.
• ATLAS Collaboration (2016) . Journal of Instrumentation, 11(04), P04008-P04008.
• James ND, Pirrie SJ, Pope AM, Barton D, Andronis L, Goranitis I, Collins S, Daunton A, McLaren D, O’Sullivan J , Parker C et al (2016) . JAMA Oncology, 2(4), 493-493.
• Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, Banks RE , Selby PJ et al (2016) . Journal of the National Cancer Institute, 108(4), ---.
• von Moos R, Body JJ, Egerdie B, Stopeck A, Brown J, Fallowfield L, Patrick DL, Cleeland C, Damyanov D, Palazzo FS , Marx G et al (2016) . Supportive Care in Cancer, 24(3), 1327-1337.
• Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martín M, Paterson A, Tonkin K , Shore N et al (2016) . Supportive Care in Cancer, 24(1), 447-455.
• Lipton A, Fizazi K, Stopeck AT, Henry DH, Smith MR, Shore N, Martin M, Vadhan-Raj S, Brown JE, Richardson GE , Saad F et al (2016) . European Journal of Cancer, 53, 75-83.
• Wagstaff J, Jones R, Hawkins R, Porfiri E, Pickering L, Bahl A, Brown J & Buchan S (2016) . Annals of Oncology, 27(1), 159-165.
• Stopeck AT, Fizazi K, Body J-J, Brown JE, Carducci M, Diel I, Fujiwara Y, Martín M, Paterson A, Tonkin K , Shore N et al (2016) . Supportive Care in Cancer, 24(1), 457-458.
• Fizazi K, Massard C, Smith M, Rader M, Brown J, Milecki P, Shore N, Oudard S, Karsh L, Carducci M , Damião R et al (2015) . European Urology, 68(1), 42-50.
• Shore N, Smith MR, Lipton A, Brown JE, Oudard S, Carducci M, Saad F, Damiao R, Zhu L, Warner D & Fizazi K (2015) . Journal of Urology, 193(4S).
• Westbrook JA, Noirel J, Brown JE, Wright PC & Evans CA (2015) . PROTEOMICS - Clinical Applications, 9(3-4), 295-300.
• Brown JE & Wood SL (2014) . European Urology, 66(3), 510-511.
• von Moos R, Body J-J, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL , Palazzo FG et al (2014) . Supportive Care in Cancer, 22(8), 2309-2310.
• Brown J, WOOD SL & WESTBROOK JA (2014) Omic-profiling in breast cancer metastasis to bone: implications for mechanisms, biomarkers and treatment..
• Nutter F, Holen I, Brown HK, Cross SS, Evans CA, Walker M, Coleman RE, Westbrook JA, Selby PJ, Brown JE & Ottewell PD (2014) . Endocrine-Related Cancer, 21(2), 327-341.
• Brown JE, Zeng L & Wilson C (2014) , 95-124.
• Palmieri C, Fullarton JR & Brown J (2013) . Clinical Cancer Research, 19(24), 6863-6872.
• Matza LS, Cong Z, Chung K, Stopeck A, Tonkin K, Brown J, Braun A, Van Brunt K & McDaniel K (2013) . Patient Preference and Adherence, 7, 855-865.
• von Moos R, Body J-J, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL , Palazzo FG et al (2013) . Supportive Care in Cancer, 21(12), 3497-3507.
• Wood SL, Westbrook JA & Brown JE (2013) . Cancer Treatment Reviews.
• Ganju V, Costa L, Fizazi K, Saad F, Brown J, von Moos R, Oudard S, Sternberg CN, Miller K, Wang H , Maniar T et al (2013) Denosumab and zoledronic acid (ZA) treatment in patients with genitourinary (GU) cancers and bone metastases. BJU INTERNATIONAL, 112, 11-11.
• Rathbone EJ, Brown JE, Marshall HC, Collinson M, Liversedge V, Murden GA, Cameron D, Bell R, Spensley S, Agrawal R , Jyothirmayi R et al (2013) . J Clin Oncol, 31(21), 2685-2691.
• James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI, Daunton A, Birtle AJ, Chakraborti PR, Ford D , Hussain SA et al (2013) . Journal of Clinical Oncology, 31(18_suppl), LBA5000-LBA5000.
• Coleman RE, Lipton A, Costa L, Cook RJ, Lee KA, Saad F, Brown JE, Terpos E, Major PP, Kohno N , Smith M et al (2013) . Journal of Bone Oncology, 2(2), 70-76.
• James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI, Daunton A, Birtle AJ, Chakraborti PR, Ford D , Hussain SA et al (2013) . Journal of Clinical Oncology, 31(15_suppl), lba5000-lba5000.
• Coleman RE, Rathbone E & Brown JE (2013) . Nat Rev Rheumatol, 9(6), 365-374.
• Karim SM, Brown J & Zekri J (2013) Efficacy of bisphosphonates and other bone-targeted agents in metastatic bone disease from solid tumors other than breast and prostate cancers. Clinical Advances in Hematology and Oncology, 11(5), 281-287.
• Coleman RE, Rathbone EJ, Marshall HC, Wilson C, Brown JE, Gossiel F, Gregory WM, Cameron D & Bell R (2012) . General Session Abstracts.
• Lipton A, Cook R, Brown J, Coleman R, Body JJ & Smith M (2012) . Clinical Oncology.
• Collinson FJ, Gregory WM, McCabe C, Howard H, Lowe C, Potrata D, Tubeuf S, Hanlon P, McParland L, Wah T , Selby PJ et al (2012) . BMC CANCER, 12.
• Richardson G, Body J-J, von Moos R, Saad F, Brown J, Lipton A, Fizazi K, Ying W, Goessl C & Richhariya A (2012) HEALTH RESOURCE UTILISATION (HRU) AND PATIENT BURDEN ASSOCIATED WITH SKELETAL-RELATED EVENTS (SRES) IN A RANDOMISED CONTROLLED TRIAL SETTING. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 8, 354-354.
• Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M , Bilynskyy B et al (2012) . EUROPEAN JOURNAL OF CANCER, 48(16), 3082-3092.
• Brown JE, Cook RJ, Lipton A & Coleman RE (2012) . Clin Cancer Res, 18(22), 6348-6355.
• Lester JE, Dodwell D, Brown JE, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM & Coleman RE (2012) . Journal of Bone Oncology, 1(2), 57-62.
• Fizazi K, Brown JE, Carducci M, Shore ND, Sieber P, Kueppers F, Karsh L, Wei R & Goessl C (2012) . Annals of Oncology, 23, ix309-ix309.
• Wood SL & Brown JE (2012) . Cancer Treatment Reviews, 38(4), 284-291.
• Matza LS, Cong Z, Chung K, Stopeck A, Tonkin KS, Brown JE, Braun AH, Van Brunt K & McDaniel K (2012) . Journal of Clinical Oncology, 30(15_suppl), e16528-e16528.
• Woodward EJ & Brown JE (2012) . Clinical Investigation, 2(5), 519-526.
• Brown JE & Coleman RE (2012) Denosumab in patients with cancer-a surgical strike against the osteoclast. Nature Reviews Clinical Oncology.
• Brown JE & Coleman RE (2012) Denosumab in patients with cancer-a surgical strike against the osteoclast. Nature Reviews Clinical Oncology, 9(2), 110-118.
• Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH , Barrios CH et al (2012) . Annals of Oncology, 23(5), 1341-1347.
• Coleman R, Woodward E, Turner L, Marshall H, Collinson M, Dodwell D, Davies C, Bell R, Cameron D & Brown J (2011) . Poster Session Abstracts.
• Collinson F, Brown J, McCabe C, Brown J, Tubeuf S, Potrata B, Hewison J, Rombach I, Selby P, Olivier C , Howard H et al (2011) . Trials, 12(S1).
• Coleman R, Costa L, Saad F, Cook R, Hadji P, Terpos E, Garnero P, Brown J, Body J-J, Smith M , Lee K-A et al (2011) . Crit Rev Oncol Hematol, 80(3), 411-432.
• Martin M, Kearney M, Bracco A & Brown J (2011) . VALUE IN HEALTH, 14(3), A158-A158.
• Cure S, Martin M, Bracco A, Brown J & Kearney M (2011) . VALUE IN HEALTH, 14(3), A158-A158.
• Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Davies C, Burkinshaw R , Houston SJ et al (2011) . Breast Cancer Res Treat, 127(2), 429-438.
• Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H , Jiang Q et al (2011) . LANCET, 377(9768), 813-822.
• Brown JE, Cleeland CS, Fallowfield LJ, Patrick DL, Fizazi K, Smith MR, Maroto JP, Michel MS, Feng A, Goessl C & Chung K (2011) . EUROPEAN UROLOGY SUPPLEMENTS, 10(2), 336-336.
• Woodward E, Jagdev S, McParland L, Clark K, Gregory W, Newsham A, Rogerson S, Hayward K, Selby P & Brown J (2011) . Bone, 48(1), 160-166.
• Collinson FJ, Vasudev NS, Berkin L, Khan MM, Selby PJ & Brown JE (2011) . Medical Oncology, 28(SUPPL. 1).
• Coleman R, Burkinshaw R, Winter M, Neville-Webbe H, Lester J, Woodward E & Brown J (2011) . Expert Opin Drug Saf, 10(1), 133-145.
• Schmidt H, Brown J, Mouritzen U, Selby P, Fode K, Svane IM, Cook GP, Mollerup DH & Geertsen PF (2010) . Clinical Cancer Research, 16(21), 5312-5319.
• Vasudev NS & Brown JE (2010) . Current Opinion in Supportive and Palliative Care, 4(3), 189-194.
• Brown JE, Sherriff JM & James ND (2010) . BJU INTERNATIONAL, 106(5), 726-727.
• Brown JE, Sherriff JM & James ND (2010) . BJU International, 106(5), 727.
• Cameron DA, Douglas S, Brown JE & Anderson RA (2010) . Breast Cancer Research and Treatment, 123(3), 805-814.
• Fizazi K, Carducci MA, Smith MR, Damião R, Brown JE, Karsh L, Milecki P, Wang H, Dansey RD & Goessl CD (2010) A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer.. J Clin Oncol, 28(18_suppl), LBA4507.
• Fizazi K, Carducci MA, Smith MR, Damião R, Brown JE, Karsh L, Milecki P, Wang H, Dansey RD & Goessl CD (2010) . Journal of Clinical Oncology, 28(18_suppl), LBA4507-LBA4507.
• Brown JE, Sherriff JM & James ND (2010) . BJU International, 105(8), 1042-1043.
• Brown JE & Coleman RE (2010) . Expert Opinion on Medical Diagnostics, 4(2), 125-138.
• Lester JE, Brown JE, Hannon RA, Ellis SP, Horsman JM, Purohit OP & Coleman RE (2010) . Bone, 46(3), 801-805.
• Sherriff JM, Brown JE & James ND (2010) . BMJ (Online), 340(7738), 118.
• Brown JE & Sim S (2010) . Neoplasia, 12(9), 685-696.
• Brown JE, Cook RJ, Lipton A, Costa L & Coleman RE (2010) Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Research and Treatment, 1-13.
• Brown JE, Lipton A, Cook RJ, Michaelson D, Coleman RE & Saad F (2009) . Journal of Clinical Oncology, 27(15_suppl), e16016-e16016.
• Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R & Major P (2008) . Cancer Treat Rev, 34(7), 629-639.
• Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA & Coleman RE (2008) . Clin Cancer Res, 14(19), 6336-6342.
• Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE & Coleman RE (2008) . CANCER, 113(1), 193-201.
• Brown JE, Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR & Coleman RE (2008) Survival benefits of zoledronic acid in patients with bone metastases from non-small cell lung cancer and high NTX levels: The role of BALP.. J Clin Oncol, 26(15_suppl), 19003.
• Lester J, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA & Coleman RE (2008) Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: Two-year results from the ARIBON study.. J Clin Oncol, 26(15_suppl), 554.
• Hall PS, Kancherla K, Sastry PSRK & Brown JE (2008) . CLINICAL ONCOLOGY, 20(4), 318-319.
• Vasudev NS, Brown JE, Brown SR, Rafiq R, Morgan R, Patel PM, O'Donnell D, Harnden P, Rogers M, Cocks K , Anderson K et al (2008) . Clinical Cancer Research, 14(6), 1775-1781.
• Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE & Coleman RE (2008) Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J THORAC ONCOL, 3(3), 228-236.
• Lester J, Dodwell D, Purohit O, Gutcher S, Ellis S, Thorpe R, Horsman J, Brown J, Hannon R & Coleman R (2008) . Cancer Treatment Reviews, 34, 51-52.
• Brown JE, McCloskey EV, Dewar JA, Body JJ, Cameron DA, Harnett AN, Ruutu M, Purohit OP, Tähtelä R & Coleman RE (2007) . Calcif Tissue Int, 81(5), 341-351.
• Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit O-P, McCloskey E & Coleman RE (2007) . Clin Cancer Res, 13(18 Pt 1), 5406-5410.
• Lipton A, Cook R, Coleman RE, Major P, Terpos E, Body J, Smith MR, Brown J & Garnero P (2007) . Journal of Clinical Oncology, 25(18_suppl), 9013-9013.
• Vasudev NS, Brown JE, Brown SR, Cocks K, O'Donnell D, Patel PM, Harnden P, Banks RE & Selby PJ (2007) . Journal of Clinical Oncology, 25(18_suppl), 10601-10601.
• Lester JE, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Purohit OP, Dodwell D & Coleman RE (2007) . Journal of Clinical Oncology, 25(18_suppl), 553-553.
• Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ & Saad F (2007) . UROLOGY, 70(2), 315-319.
• Brown JE, Ellis SP, Silcocks P, Blumsohn A, Gutcher SA, Radstone C, Hancock BW, Hatton MQ & Coleman RE (2006) . Clin Cancer Res, 12(21), 6480-6486.
• Saad F, Coleman RE, Cook R, Smith MR, Brown JE, Hei JY & Chen YM (2006) . Journal of Clinical Oncology, 24(18_suppl), 4555-4555.
• Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F & Smith MR (2006) . CLIN CANCER RES, 12(11), 3361-3367.
• Santini D, Vincenzi B, Hannon RA, Brown JE, Dicuonzo G, Angeletti S, La Cesa A, Coleman RE, Tonini G, Budillon A , Caraglia M et al (2006) Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. ONCOL REP, 15(5), 1351-1357.
• Greenfield DM, Wright J, Brown JE, Hancock BW, Davies HA, O'Toole L, Eiser C, Coleman RE & Ross RJ (2006) . Br J Cancer, 94(4), 469-472.
• Hashemizadeh SA, Wells JPR, Murzyn P, Brown J, Jones BD, Wang T, Parbrook PJ, Fox AM, Mowbray DJ & Skolnick MS (2005) . APPL PHYS LETT, 87(23).
• Coleman RE, Major P, Lipton A, Brown JE, Lee K-A, Smith M, Saad F, Zheng M, Hei YJ, Seaman J & Cook R (2005) . J Clin Oncol, 23(22), 4925-4935.
• Brown JE, Lester J, Ellis S, Gutcher S, Turner L, Purohit O-P, Hancock B & Coleman R (2005) . Journal of Clinical Oncology, 23(16_suppl), 8023-8023.
• Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee K-A, Zheng M, Hei Y-J & Coleman RE (2005) . J Natl Cancer Inst, 97(1), 59-69.
• Brown JE, McCloskey E, Dewar JA, Body J-J, Cameron DA, Purohit OP-K, Harnett A, Tahtela R, Kurkilahti M & Coleman RE (2004) . Journal of Clinical Oncology, 22(14_suppl), 8056-8056.
• Brown JE, McCloskey E, Dewar JA, Body J-J, Cameron DA, Purohit OP-K, Harnett A, Tahtela R, Kurkilahti M & Coleman RE (2004) . Journal of Clinical Oncology, 22(14_suppl), 8056-8056.
• Brown JE & Coleman RE (2004) . American Journal of Cancer, 3(4), 265-265.
• Brown JE, Neville-Webbe H & Coleman RE (2004) . Endocr Relat Cancer, 11(2), 207-224.
• Galasko CSB (2004) . American Journal of Cancer, 3(4), 265-265.
• Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP & Coleman RE (2003) . Br J Cancer, 89(11), 2031-2037.
• Brown JE & Coleman RE (2003) . American Journal of Cancer, 2(4), 269-281.
• Brown JE, Hatton MQ, Melchers R, Goldstraw P & Coleman RE (2003) . Clin Oncol (R Coll Radiol), 15(7), 371-377.
• Brown JE & Coleman RE (2002) . Breast Cancer Res, 4(1), 24-29.
• Brown JE & Coleman RE (2002) . Breast, 11(5), 375-385.
• Brown JE, Olujohungbe A, Chang J, Ryder WDJ, Morganstern GR, Chopra R & Scarffe JH (2000) . British Journal of Haematology, 110(4), 1010-1012.
• Brown J & McIllmurray M (2000) Career focus on medical oncology. BMJ, 11, 2-3.
• Brown J (2000) Cancer Genetics: Friend or foe of the junior doctor. Morecambe Bay Medical Journal, 8, 272-272.
• Brown J (2000) Photodynamic therapy, its impact in clinical practice. Photodynamics, 3(2), 2-5.
• Brown JE, Brown SB & Vernon DI (1999) . Expert Opinion on Investigational Drugs, 8(12), 1967-1979.
• Brown JE, Brown SB & Vernon DI (1999) Photodynamic therapy - new light on cancer treatment. JOURNAL OF THE SOCIETY OF DYERS AND COLOURISTS, 115(9), 249-253.
• Huang Q, Mitchell C, Theodoulou E, Lee ACK & Brown J () . Journal of Cancer Survivorship.
• Collinson F, Royle K-L, Swain J, Ralph C, Maraveyas A, Eisen T, Nathan P, Jones R, Meads D, Min Wah T , Martin A et al () . Health Technology Assessment, 1-171.
• Culliford R, Lawrence SED, Mills C, Tippu Z, Chubb D, Cornish AJ, Browning L, Kinnersley B, Bentham R, Sud A , Pallikonda H et al () . Nature Communications, 15(1).
• Evans H, Andrews R, Abedi FA, Sprules A, Trend J, Lovric G, Green A, Chantry A, Clarkin C, Brown J & Lawson M () . JBMR Plus.
• McNaught E, Reale S, Bourke L, Brown JE, Collinson M, Day F, Hewison J, Farrin AJ, Ibeggazene S, Innes AQ , Mason E et al () . Trials, 25(1).
• Brown J, Harrow B, Marciniak A, McCarthy C, Houchard A, Cirneanu L & Protheroe A () . Drugs - Real World Outcomes.
• Brown J, Paggiosi MA, Rathbone E, Gregory W, Bertelli G, Din O, McCloskey E, Dodwell D, Cameron D, Eastell R & Coleman R () . Journal of Bone and Mineral Research.
• Moamin MR, Allen R, Woods SL, Brown JE, Nunns H, Juncker-Jensen A & Lewis CE () . Frontiers in Immunology, 14.
• Conroy S, Catto JWF, Bex A, Brown J, Cartledge J, Fielding A, Jones RJ, Khoo V, Nicol D, Stewart GD , Sullivan M et al () . BJU International.
• Saleh L, Ottewell PD, Brown JE, Wood SL, Brown NJ, Wilson C, Park C, Ali S & Holen I () . Cancers, 15(8), 2211-2211.
• Kwan A, Howard F, Winder N, Atkinson E, Jailani A, Patel PB, Allen R, Ottewell PD, Shaw GC, Conner J , Wilson C et al () . Future Pharmacology, 2(4), 444-459.
• Brown JE () . JAMA Oncology.
• Zhong J, Palkhi E, Buckley DL, Collinson FJ, Ralph C, Jagdev S, Vasudev NS, Swain J, Brown JE & Wah TM () . Diagnostics, 11(7), 1302-1302.
• Wood SL & Brown JE () . Cancers, 12(8), 2109-2109.
• Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, Brawley CD, Calvert J, Chowdhury S, Cook A , Cross W et al () . Annals of Oncology, 1-12.
• Bourke L, Turner R, Greasley R, Sutton E, Steed L, Smith D, Brown J, Kelly B, Hulme C, Greenfield D , Persad R et al () . PLOS ONE, 13(7), e0197606-e0197606.

Chapters

• Wyld L, Cutress R & Morgan J (2024) , 50 Landmark Papers every Breast Surgeon Should Know (pp. 243-248). CRC Press
• Wyld L, Cutress R & Morgan J (2024) , 50 Landmark Papers every Breast Surgeon Should Know (pp. 165-170). CRC Press
• Wyld L, Cutress R & Morgan J (2024) , 50 Landmark Papers every Breast Surgeon Should Know (pp. 237-242). CRC Press
• Wyld L, Cutress R & Morgan J (2024) , 50 Landmark Papers every Breast Surgeon Should Know (pp. 159-164). CRC Press
• Wood SL, Lopez-Guajardo A & Brown JE (2022) , Bone Cancer (pp. 783-803). Elsevier
• Arias-Pinilla GA & Brown J (2022) , Bone Cancer (pp. 987-1002). Elsevier
• Brown J, Wood S & Lopez A (2021) Identification of new therapeutic targets of bone cancers by proteomic strategies In Heymann D (Ed.), Bone Cancer Bone Sarcomas and Bone Metastases - From Bench to Bedside (pp. 783-803). Elsevier
• Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, Guise T, Colangeli S, Capanna R & Costa L (2020)
• Coleman RE, Brown J & Holen I (2020) , Abeloff's Clinical Oncology (pp. 809-830.e3). Elsevier
• Hossain M, Pezaro C, Walsh J, Rathbone E & Brown J (2019) Metabolic complications In Young A, Board R, Leonard P, Cooksley T, Stewart A & Michie C (Ed.), Problem solving in acute oncology (pp. 84-88). ebn Health
• Abdelhay E, Adiseshaiah PP, Aglietta M, Allègra M, Ascierto PA, Bastus NC, Basudan A, Berghuis AMS, Biasco G, Binato R , Borah A et al (2019) , Oncogenomics (pp. xv-xx). Elsevier
• Schoon JJ, Wood SL & Brown JE (2019) , Oncogenomics (pp. 551-563). Elsevier
• Brown J, Wood S, Salawu A, Kroening H & D'Oronzo S (2019) In Martini L & Huhtaniemi I (Ed.), Encyclopedia of Endocrine Diseases (pp. 310-319). Oxford: Elsevier.
• Wood S, Salawu A, Kroening H, D’Oronzo S & Brown J (2019) , Encyclopedia of Endocrine Diseases (pp. 310-319). Elsevier
• Handforth C, D'Oronzo S & Brown J (2018) (pp. 799-808). Wiley
• Schoon JJ, Wood SL & Brown JE (2018) , Oncogenomics: From Basic Research to Precision Medicine (pp. 551-563).
• Kwan A & Brown JE (2018) , Breast Cancer Management for Surgeons (pp. 673-679). Springer International Publishing
• Salawu AT, Handforth C & Brown JE (2017) , Management of Prostate Cancer (pp. 343-356). Springer International Publishing
• Brown J (2014) In Vassiliou V, Chow E & Kardamakis D (Ed.), Bone Metastases A translational and Clinical Approach (pp. 95-124). Springer Netherlands
• Wood SL & Brown JE (2014) In Vassiliou V, Chow E & Kardamakis D (Ed.), Bone Metastases (pp. 125-153). Springer Netherlands
• Rathbone E, Brown J & Walsh J (2013) Metabolic Complications In Marshall E, Clark P, Selby P & Young A (Ed.), Problem Solving in Acute Oncology Clinical Publishing
• Brown J & von Poznak C (2010) Expert Commentary for Breast Disease. In - (Ed.), A Year Book Quarterly 21 (pp. 1-1).
• Brown JE & Chow E (2009) , Bone Metastases (pp. 93-116). Springer Netherlands
• Brown J, Brown SB, Brown S & Vernon DI (1999) The role of photodynamic therapy in cancer treatment opportunities and limitations In Griffiths J (Ed.), Colour science Volume (pp. 200-210).
• Coleman RE & Brown JE () , Textbook of Bone Metastases (pp. 105-121). John Wiley & Sons, Ltd

Conference proceedings papers

• Manickavasagar T, Kelly-Morland C, Wah TM, Nathan P, Brown J & Goh V (2024) Enhancement and Size-based Response Criteria for Evaluating Tyrosine Kinase Inhibitor Dosing Strategy in Metastatic Renal Cancer: Prospective Imaging Study from the UK STAR Trial. CLINICAL ONCOLOGY, Vol. 36(1) (pp E78-E79)
• Jones C, Gray S, Brown M, Brown J, Mc CE, Rai B, Clarke N & Sachdeva A (2023) Fracture and fall risk in men with advanced or metastatic prostate cancer treated with novel androgen receptor signalling inhibitors: A systematic review and meta-analysis of randomised controlled trials. EUROPEAN UROLOGY, Vol. 83
• Jones C, Sachdeva A, Murphy L, Murray M, Brown L, Brown J, Mc CE, Attard G, Parmar M, James N , Sydes MR et al (2023) Clinical fracture incidence in metastatic hormone-sensitive prostate cancer and risk-reduction following addition of zoledronic acid to androgen deprivation therapy with or without docetaxel: Long-term results from the STAMPEDE trial. EUROPEAN UROLOGY, Vol. 83
• Pinto Marin A, Trilla L, Miranda J, Vasudev NS, García E, López-Vacas R, Miranda N, Wilson M, López-Camacho E, Pertejo-Fernández A , Lumbreras Herrera MI et al (2022) . Annals of Oncology, Vol. 33 (pp S1220-S1220)
• Sprules AR, Latif NB, Brown JE, Gartland A & Wang N (2021) . Cancer Research, Vol. 81(13_Supplement) (pp 2904-2904)
• Al-janabi H, Pu X, Muthana M, Wang N, Crespo M, Gurel B, De Bono J, Brown JE & Lewis CE (2021) . Cancer Research, Vol. 81(13_Supplement) (pp 2797-2797)
• Sprules AR, Latif NB, Brown JE, Gartland A & Wang N (2021) Mechanical loading induced osteogenic response does not interfere with the colonization of breast cancer in bone.. CANCER RESEARCH, Vol. 81(13)
• Al-Janabi H, Pu X, Muthana M, Wang N, Crespo M, Gurel B, De Bono J, Brown JE & Lewis CE (2021) Changes in the phenotype of macrophages and CD8+T Cells in the perivascular niche of prostate tumours following androgen deprivation.. CANCER RESEARCH, Vol. 81(13)
• Winter M, Kendall J, Brown S, Rathbone E, Wilson C, Howell S, Twelves C, Palmieri C, Anand A, MacPherson I , Coleman R et al (2021) A randomised phase IB/IIA study of CApecitabine plus Radium-223 in breast cancer patients with BONe metastases (CARBON) - Safety and preliminary efficacy findings. CANCER RESEARCH, Vol. 81(4)
• Baron-Hay S, Theodoulou E, Porter I, Wilson C, Holen I, Harper-Wynne C & Brown J (2020) . Poster Session Abstracts
• Saleh L, Ottewell PD, Brown JE, Wood SL, Brown NJ, Wilson C, Park C & Holen I (2020) Preventing the progression of breast cancer bone metastasis by CDK inhibition. BREAST CANCER RESEARCH AND TREATMENT, Vol. 180(2) (pp 537-538)
• Brown JE, Handforth C, Walsh J, Pezaro C, Sydes MR, Clarke NW, James ND & McCloskey E (2019) . Annals of Oncology, Vol. 30(Suppl 5) (pp v334-v335). Barcelona, Spain, 27 September 2019 - 1 October 2019.
• Pu X, AL-Janabi H, Wang N, Muthana M, Brown J & Lewis C (2019) . Tumor Biology
• Pu X, AL-Janabi H, Wang N, Muthana M, Brown J & Lewis C (2019) . Tumor Biology
• Ottewell PD, Lefley DV, Freeman K, Gregory WM, Hanby AM, Spicer-Hadlington AR, Liu X, Bradbury SM, Hambley L, Allocca G , Cookson V et al (2019) . Poster Session Abstracts
• Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Haider M-T, Rhee CS, Qin Y, Holen I, Gregory WM , Brown JE et al (2018) . Early Clinical Opportunities
• Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Haider M-T, Rhee CS, Qin Y, Holen I, Gregory WM , Brown JE et al (2018) Plasma G-CSF levels are predictive of lack of response to zoledronic acid treatment in reducing breast cancer recurrence.. MOLECULAR CANCER RESEARCH, Vol. 16(8) (pp 68-69)
• Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G, Brunt AM, Kuemmel S , Ruiz Cabrero I et al (2018) . General Session Abstracts
• Kelly-Morland C, Zhong J, Goh V, Wah T, Ralph C, Thistlethwaite F, Patel P, Nathan P, Eisen T, Gregory W , McParland L et al (2017) Prospective comparison of RECIST and alternative response assessment criteria in the evaluation of metastatic renal cell cancer patients from phase II of the multi-centre randomised STAR trial. ANNALS OF ONCOLOGY, Vol. 28
• Shepherd STC, Hall P, Brown JE, Larkin JMG, Jones RJ, Ralph C, Hawkins RE, Chowdhury S, Boleti E, Bahl A , Fife K et al (2017) . Journal of Clinical Oncology, Vol. 35(15_suppl) (pp e16061-e16061)
• Trainor S, Wah T, Ralph C, McParland L, Gregory W, Brown J, Best E, Handforth C, Chan K, Cook H , Hiley V et al (2017) . Clinical Oncology, Vol. 29(3) (pp e89-e89)
• Smith MR, Brown JE, Fizazi K, Klotz L, Marx GM, Wang H, Warner D & Lipton A (2015) . Journal of Clinical Oncology, Vol. 33(7_suppl) (pp 267-267)
• Powles T, Oudard S, Escudier BJ, Brown JE, Hawkins RE, Castellano DE, Ravaud A, Staehler MD, Rini BI, Lin W , O'Keeffe B et al (2014) . Journal of Clinical Oncology, Vol. 32(15_suppl) (pp 4525-4525)
• Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Marshall H, Banks RE, Selby PJ, Coleman RE & Brown JE (2013) . Poster Session Abstracts
• Von Moos R, Fallowfield L, Cleeland C, Patrick D, Body JJ, Brown JE, Marx G, Zhou Y, Balakumaran A & Qian YI (2013) Effect of skeletal-related events on pain interference in patients with solid tumors and bone metastases. EUROPEAN JOURNAL OF CANCER, Vol. 49 (pp S269-S269)
• Von Moos R, Stopeck A, Fizazi K, Cleeland C, Brown JE, Oudard S, Costa L, Wang H & Braun A (2013) Skeletal-related events in patients with solid tumors receiving denosumab or zoledronic acid by baseline pain status: Results from three phase 3 trials. EUROPEAN JOURNAL OF CANCER, Vol. 49 (pp S268-S268)
• Brown J, Saad F, Stopeck A, Fizazi K, Henry D, Diel I, De Boer R, Wang H & Braun A (2013) Risk factors for developing osteonecrosis of the jaw (ONJ) in patients receiving denosumab or zoledronic acid for bone metastases: Results from three phase 3 trials. EUROPEAN JOURNAL OF CANCER, Vol. 49 (pp S268-S269)
• James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI, Daunton A, Birtle AJ, Chakraborti PR, Ford D , Hussain SA et al (2013) Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(18)
• Fallowfield L, Cleeland CS, Von Moos R, Patrick D, Body J-J, Egerdie B, Stopeck A, Brown JE, Marx GM, Palazzo F , Damyanov DI et al (2013) Impact of skeletal-related events on pain and analgesic use in patients with solid tumors and bone metastases.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
• James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI, Daunton A, Birtle AJ, Chakraborti PR, Ford D , Hussain SA et al (2013) Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial trapeze trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
• Lipton A, Saad F, Van Poznak CH, Brown JE, Stopeck A, Fizazi K, Henry DH, Shore ND, Diel IJ, Tonkin KS , De Boer RH et al (2013) Incidence of osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: Results from three phase III trials.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
• Costa L, Fizazi K, Saad F, Brown JE, Von Moos R, Oudard S, Sternberg CN, Ganju V, Miller K, Wang H , Maniar T et al (2013) Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
• Kueppers F, Fizazi K, Brown J, Carducci M, Shore N, Sieber P, Karsh L, Wei R & Goessl C (2013) 2-year open-label extension phase results from the pivotal phase 3 study of denosumab in patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with denosumab or zoledronic acid. BJU INTERNATIONAL, Vol. 111 (pp 91-92)
• Fizazi K, Brown JE, Carducci M, Shore ND, Sieber P, Kueppers F, Karsh L, Wei R & Goessl C (2012) DENOSUMAB IN PATIENTS WITH METASTATIC PROSTATE CANCER PREVIOUSLY TREATED WITH DENOSUMAB OR ZOLEDRONIC ACID: 2-YEAR OPEN-LABEL EXTENSION PHASE RESULTS FROM THE PIVOTAL PHASE 3 STUDY. ANNALS OF ONCOLOGY, Vol. 23 (pp 309-309)
• Matza LS, Cong Z, Chung K, Stopeck A, Tonkin KS, Brown JE, Braun AH, Van Brunt K & McDaniel K (2012) Health state preferences associated with subcutaneous injections and intravenous infusions for treatment of bone metastases. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
• Fizazi K, Massard C, Smith MR, Rader ME, Brown JE, Milecki P, Shore ND, Oudard S, Karsh LI, Carducci MA , Damiao R et al (2012) Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
• Body J-J, Von Moos R, Saad F, Richardson GE, Brown JE, Lipton A, Fizazi K, Ying W, Goessl CD & Richhariya A (2012) Health resource utilization and patient burden associated with SREs in a randomized controlled trial setting. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
• Stopeck AT, Richardson G, Siena S, Lipton A, Brown J, Fizazi K, Henry D, Saad F, Ke C & Braun A (2012) . EUROPEAN JOURNAL OF CANCER, Vol. 48 (pp S8-S8)
• Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Saad F, Yardley D, Maroto P, Ke C & Jun S (2011) . EUROPEAN JOURNAL OF CANCER, Vol. 47 (pp S240-S240)
• Brown JE, Cameron D, Coleman R, Fallowfield L, Holen I, Jones AL & Thompson A (2011) UK INNOVATORS IN BREAST CANCER: AN INITIATIVE TO SUPPORT THE NEXT GENERATION OF BREAST CANCER RESEARCHERS (ON BEHALF OF PAST AND PRESENT 'UK INNOVATORS'). ANNALS OF ONCOLOGY, Vol. 22 (pp 58-58)
• Brown JE, Cameron D, Coleman R, Fallowfield L, Holen I, Jones AL & Thompson A (2011) UK INNOVATORS IN BREAST CANCER: AN INITIATIVE TO SUPPORT THE NEXT GENERATION OF BREAST CANCER RESEARCHERS (ON BEHALF OF PAST AND PRESENT 'UK INNOVATORS'). ANNALS OF ONCOLOGY, Vol. 22
• Wood SL, Westbrook JA, Peng J, Selby PJ & Brown JE (2011) . BONE, Vol. 48(1) (pp S50-S51)
• Brown J, Carducci M, Fizazi K, Smith M, Damiao DR, Karsh L, Milecki P, Wang H, Dansey R & Goessl C (2011) . BONE, Vol. 48(1) (pp S16-S16)
• Brown JE, Barrios CH, Diel IJ, Facon T, Fizazi K, Ibrahim T, Saad F, Senecal F, Stemmer SM, Stopeck A , Takahashi S et al (2011) . BONE, Vol. 48(1) (pp S18-S19)
• Westbrook JA, Peng J, Cairns DA, Ottewell PD, Holen I, Coleman RE, Selby PJ, Banks RE & Brown JE (2011) . BONE, Vol. 48(1) (pp S33-S33)
• Woodward EJ, Brown JE, Barnfield MC, Taylor J, Blake GM, Fogelman I, Turner LA, Thorpe H, Dodwell D, Joffe JK & Coleman RE (2011) . BONE, Vol. 48(1) (pp S29-S29)
• Body J, Cook R, Costa L, Brown J, Terpos E, Saad F, Lipton A & Coleman R (2011) . BONE, Vol. 48(1) (pp S20-S21)
• Coleman RE, Woodward EJ, Brown JE, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Davies C, Burkinshaw R , Houston SJ et al (2011) . BONE, Vol. 48(1) (pp S29-S29)
• Michaelson D, Kpamegan EE, Perez JR & Brown J (2010) ZOLEDRONIC ACID (ZOL) REDUCES THE INCIDENCE OF SKELETAL-RELATED EVENT (SRES) AND MAY IMPROVE SURVIVAL IN PATIENTS WITH BONE METASTASES (METS) FROM RENAL CELL CARCINOMA (RCC): A RETROSPECTIVE INTEGRATED ANALYSIS. ANNALS OF ONCOLOGY, Vol. 21 (pp 287-287)
• Brown J, Lipton A, Cook R, Michaelson D, Coleman R & Saad F (2010) . BONE, Vol. 47 (pp S312-S312)
• Costa L, Cook R, Body J, Brown J, Terpos E, Saad F, Lipton A & Coleman R (2010) . BONE, Vol. 47 (pp S302-S303)
• Body J, Cook R, Costa L, Brown J, Terpos E, Saad F, Lipton A & Coleman R (2010) . BONE, Vol. 47 (pp S311-S312)
• Din OS, Brown JE, Ellis SP, Gutcher SA & Coleman RE (2010) . BONE, Vol. 47 (pp S311-S311)
• Woodward EJ, Brown JE, Ellis SP, Gutcher S, Lester JE, Purohit O & Coleman RE (2010) . BONE, Vol. 47 (pp S310-S311)
• Brown JE, Lipton A, Cook RJ, Michaelson D, Coleman RE & Saad F (2009) Correlation of N-telopeptide of type I collagen (NTX) with survival and fractures in patients (pts) with bone metastases from renal cell carcinoma (RCC). JOURNAL OF CLINICAL ONCOLOGY, Vol. 27(15)
• Brown J, Cook R, Hirsh V & Major P (2008) RISK FACTORS FOR SKELETAL-RELATED EVENT (SRES) IN ZOLEDRONIC ACID-TREATED PATIENTS WITH BONE METASTASES (METS) FROM NON-SMALL CELL LUNG CANCER (NSCLC). ANNALS OF ONCOLOGY, Vol. 19 (pp 275-275)
• Brown JE, Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR & Coleman RE (2008) . JOURNAL OF CLINICAL ONCOLOGY, Vol. 26(15)
• Lester J, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA & Coleman RE (2008) . JOURNAL OF CLINICAL ONCOLOGY, Vol. 26(15)
• Coleman R, Brown J & Cook R (2008) Serum lactate dehydrogenase (LDH) is a significant prognostic variable for survival in patients with metastatic breast cancer - a multivariate analysis. EJC SUPPLEMENTS, Vol. 6(7) (pp 189-189)
• Clarke K, Jagdev S, Newsham A, Lister J, Hayward K, Sastry K, Selby P & Brown J (2008) . CANCER TREATMENT REVIEWS, Vol. 34 (pp S81-S82)
• Kandukurti K, Zekri J, Marples M & Brown J (2008) . CANCER TREATMENT REVIEWS, Vol. 34 (pp S78-S78)
• Brown J, Cook R & Coleman R (2008) . CANCER TREATMENT REVIEWS, Vol. 34 (pp S79-S79)
• Lester J, Dodwell D, Purohit O, Gutcher S, Ellis S, Thorpe R, Horsman J, Brown J, Hannon R & Coleman R (2008) . CANCER TREATMENT REVIEWS, Vol. 34 (pp S51-S51)
• Coleman R, Brown J & Cook R (2008) . CANCER TREATMENT REVIEWS, Vol. 34 (pp S78-S79)
• Hirsh V, Major P, Lipton A, Cook R, Langer C, Smith M, Brown J & Coleman R (2008) . CANCER TREATMENT REVIEWS, Vol. 34 (pp S85-S85)
• Vasudev NS, Brown JE, Brown SR, Cocks K, O'Donnell D, Patel PM, Harnden P, Banks RE & Selby PJ (2007) Preoperative sodium concentration as a possible predictor of survival in patients with renal cell carcinoma. JOURNAL OF CLINICAL ONCOLOGY, Vol. 25(18)
• Lipton A, Cook R, Coleman RE, Major P, Terpos E, Body J, Smith MR, Brown J & Garnero P (2007) Normalization of bone markers and improved survival during zoledronic acid therapy. JOURNAL OF CLINICAL ONCOLOGY, Vol. 25(18)
• Lester JE, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Purohit OP, Dodwell D & Coleman RE (2007) Effect of monthly oral ibandronate on anastrozole-induced bone loss during adjuvant treatment for breast cancer: One-year results from the ARIBON study. JOURNAL OF CLINICAL ONCOLOGY, Vol. 25(18)
• Lester J, Horsman J, Purohit OP, Brown JE & Coleman RE (2006) . BONE, Vol. 38(3) (pp S79-S79)
• Lester JE, Penty L, Brown JE, Radstone C, Purohit OP & Coleman RE (2006) . BONE, Vol. 38(3) (pp S79-S80)
• Brown JE, Lester J, Ellis S, Gutcher S, Turner L, Purohit O & Coleman RE (2006) . BONE, Vol. 38(3) (pp S70-S70)
• Lester JE, Gutcher SA, Ellis S, Thorpe R, Horsman J, Brown JE, Purohit OP, Dodwell D & Coleman RE (2006) The ARIBON study: Reversal of anastrozole (Arimidex) induced bone loss with oral monthly ibandronate (Bondronat) treatment during adjuvant therapy for breast cancer.. CANCER TREATMENT REVIEWS, Vol. 32 (pp S48-S49)
• Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit O & Coleman RE (2006) Infrequent zoledronic acid produces sustained increases in bone mineral density (BMD) in patients with cancer treatment induced bone loss (CTIBL). CANCER TREATMENT REVIEWS, Vol. 32 (pp S19-S19)
• Holen I, Hannon RA, Ellis SP, Coleman RE & Brown JE (2006) Effects of clodronate on serum osteoprotogerin (OPG) in patients with metastatic bone disease. CANCER TREATMENT REVIEWS, Vol. 32 (pp S40-S40)
• Lipton A, Coleman RE, Major P, Brown JE, Lee KA, Smith M, Saad F, Chen YM, Hei YJ & Cook R (2005) Baseline N-telopeptide levels correlate with risk of skeletal morbidity in patients with multiple myeloma during zoledronic acid therapy.. BLOOD, Vol. 106(11) (pp 964A-965A)
• Cook RJ, Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Chen YM & Hei YJ (2005) Prognostic significance of biochemical markers of bone metabolism in patients with bone lesions from multiple myeloma (MM).. BLOOD, Vol. 106(11) (pp 335B-335B)
• Brown JE, Lester J, Ellis S, Gutcher S, Turner L, Purohit OP, Hancock B & Coleman R (2005) Can an annual infusion of zoledronic acid protect against cancer-treatment induced bone loss (CTIBL)?. JOURNAL OF CLINICAL ONCOLOGY, Vol. 23(16) (pp 734S-734S)
• Brown JE, Ellis SP, Gutcher SA, Purohit OP, Turner L, Neville-Webbe HL & Coleman RE (2005) Using bone turnover markers to direct bisphosphonate therapy: Is this a feasible approach?. CANCER TREATMENT REVIEWS, Vol. 31 (pp S30-S30)
• Lester JE, Brown JE, Ellis SP, Gutcher S, Horsman JM & Coleman RE (2005) The use of point of care devices for the monitoring of urinary NTX levels in metastatic breast cancer. CANCER TREATMENT REVIEWS, Vol. 31 (pp S52-S53)
• Brown JE, Ellis SP, Silcock P, Gutcher SA, Radstone C, Blumsohn A, Hancock BW, Hatton MQ & Coleman RE (2005) Do long-term cancer survivors, treated for testicular cancer or lymphoma, suffer chemotherapy-induced bone loss?. CANCER TREATMENT REVIEWS, Vol. 31 (pp S46-S46)
• Ellis SP, Brown JE, Everard JE, Neville-Webbe HL, Hancock BW & Coleman RE (2005) A study to determine whether the bisphosphonate zoledronic acid can be shown to exert a direct anti tumour effect in vivo. CANCER TREATMENT REVIEWS, Vol. 31 (pp S48-S49)
• Ellis SP, Brown JE, Gutcher SA, Hancock BW, Hatton MQ, Rigby AS & Coleman RE (2004) An investigation of the long-term effects of chemotherapy on bone in male long-term cancer survivors. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1587-1587)
• Cook RJ, Coleman RE, Saad F, Smith M, Lipton A, Lee KA, Brown JE, Zheng M, Hei YJ & Major P (2004) The predictive value of bone resorption and formation markers in patients with prostate cancer metastatic to bone. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1596-1596)
• Brown JE, Cook RJ, Major P, Lipton A, Lee KA, Zheng M, Hei YJ & Coleman RE (2004) The prognostic significance of biochemical markers of bone metabolism in patients with bone metastases from solid tumors other than breast and prostate cancer. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1596-1596)
• Brown JE, Ellis S, Gutcher S, Lester JE, Turner L, Purohit OP, Hancock BW & Coleman RE (2004) Effect of an annual infusion of zoledronic acid on bone mineral density in cancer survivors following antineoplastic therapy. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1596-1596)
• Brown JE, McCloskey E, Dewar JA, Body JJ, Cameron DA, Purohit OPK, Harnett A, Tahtela R, Kurkilahti M & Coleman RE (2004) A double blind, parallel, placebo controlled, dose ranging study on efficacy and safety of oral clodronate in cancer induced osteolysis measured by biochemical markers of bone resorption.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 22(14) (pp 743S-743S)
• Brown JE (2004) Prediction of skeletal complications in metastatic bone disease and strategies for management of treatment-induced bone loss. BRITISH JOURNAL OF CANCER, Vol. 91 (pp S20-S20)
• Brown J, Lester J, Ellis S, Gutcher S, Turner L, Purohit O, Hancock B & Coleman R (2004) Bone loss in long term cancer survivors. A pilot study to evaluate the effect of annual intravenous zoledronic acid on bone mineral density (BMD) and bone turnover markers. BONE, Vol. 34 (pp S93-S93)
• Goodhart LM, Brown JE, Ellis S, Gutcher S, Purohit OP & Coleman RE (2003) Development of a touch screen questionnaire approach for measurement of pain assessment scales in cancer patients with bone metastasis. BRITISH JOURNAL OF CANCER, Vol. 88 (pp S67-S67)
• Brown JE, Ellis S, Gutcher S, Turner L, Purohit OP & Coleman RE (2002) Bone marker directed bisphosphonate therapy in metastatic bone disease. BRIT J CANCER, Vol. 86 (pp S19-S19)
• Brown JE, Ellis S, Gutcher S, Thompson C, Purohit OP & Coleman RE (2002) Relationship between bone resorption and skeletal events in metastatic done disease. BONE, Vol. 30(3) (pp 47S-47S)
• Brown JE, Ellis S, Gutcher S, Turner L, Purohit OP & Coleman RE (2002) Bone marker directed bisphosphonate treatment. A pilot study to determine feasibility. BONE, Vol. 30(3) (pp 47S-47S)

Reports

• Brown J (2023) Implementing frailty assessment and management in oncology services
• Brown J (2022) Expert Panel: evaluation of the Government’s commitments in the area of cancer services in England

Other

• Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2023) .

Preprints

• Al-janabi H, Moyes K, Allen R, Fisher M, Crespo M, Gurel B, Rescigno P, De Bono J, Nunns H, Bailey C , Juncker-Jensen A et al (2024) , Cold Spring Harbor Laboratory.
• Huang Q, Mitchell C, Theodoulou E, Lee A & Brown J (2024) , Research Square Platform LLC.
• () , Cold Spring Harbor Laboratory.
• Reale S, Turner R, Sutton E, Taylor S, Bourke L, Morrissey D, Brown J, Rosario D, Steed L & NA OBOTSTAMINAC-I () , Research Square Platform LLC.
• Reale S, Turner R, Sutton E, Steed L, Taylor S, Morrissey D, Doherty P, Greenfield D, Collinson M, Hewison J , Brown J et al () , Research Square Platform LLC.
• Turner R, Arden M, Reale S, Sutton E, Taylor S, Bourke L, Greenfield D, Morrissey D, Brown J, Doherty P , Rosario D et al () , Research Square Platform LLC.